GlaxoSmithKline pleased with recent Nucala results
10th Sep 2018 08:39
(Sharecast News) - GlaxoSmithKline announced results on Monday from an indirect treatment comparison of the licensed doses of Nucala (mepolizumab), compared to benralizumab and reslizumab, in patients with severe eosinophilic asthma.
Read moreMore work needed for mepolizumab application, says GlaxoSmithKline
10th Sep 2018 07:22
(Sharecast News) - GlaxoSmithKline has received a 'complete response letter' from the United States Food and Drug Administration regarding its application for mepolizumab, it announced on Monday.
Read moreThursday broker round-up
30th Aug 2018 13:50
(Sharecast News) - Bellway: Deutsche Bank upgrades to buy with a target price of 2,745p
Read moreGSK gets European approval for Nucala to treat children
30th Aug 2018 09:26
(Sharecast News) - The European commission has approved GlaxoSmithKline's Nucala treatment for use with children who have severe asthma.
Read moreFriday broker round-up
24th Aug 2018 14:41
(Sharecast News) - Antofagasta: RBC Capital Markets upgrades to outperform with a target price of 950p.
Read moreGSK's once-monthly HIV treatment proves trial success
15th Aug 2018 07:32
(Sharecast News) - GlaxoSmithKline has seen positive results from clinical trials of its once-monthly injectable treatment for HIV.
Read moreGlaxoSmithKline nabs HSBC's Iain Mackay as its next CFO
7th Aug 2018 07:22
(Sharecast News) - GlaxoSmithKline announced on Tuesday that Iain Mackay has been appointed its next chief financial officer, and an executive director to its board, with both positions starting on 14 January next year.
Read moreWednesday broker round-up
1st Aug 2018 13:19
(Sharecast News) - Rightmove: Berenberg downgrades to sell with a target price of 4,100p.
Read moreThursday broker round-up
26th Jul 2018 13:01
(Sharecast News) - Beazley: Berenberg upgrades to buy with a target price of 640p.
Read moreGlaxoSmithKline's COPD biologic rejected by FDA advisory board
26th Jul 2018 08:16
(Sharecast News) - GlaxoSmithKline's application to market a new biologic drug for chronic obstructive pulmonary disease has been rejected by the advisory board of the US medical watchdog, though the company remains confident in the drug as a COPD treatment.
Read moreGSK bets $300m on tie-up with gene-tester 23andMe
25th Jul 2018 11:06
(Sharecast News) - GlaxoSmithKline has invested $300m (£228m) in 23andMe, a Silicon Valley gene-testing company, as the UK drugs giant looks to genetics to improve growth in its pharmaceuticals division.
Read moreGSK to apply for new two-drug HIV combo after Gemini trial success
24th Jul 2018 10:15
(Sharecast News) - Glaxosmithkline's ViiV Healthcare joint venture reported positive results from trials of two of its key HIV treatments on Tuesday.
Read moreMonday newspaper round-up: De La Rue, Tesco, Glaxo Smith Kline
23rd Jul 2018 06:40
(Sharecast News) - The hedge fund pushing for change at passport and banknote maker De La Rue has increased its stake and ramped-up pressure on the boss to overhaul the firm. Crystal Amber is now understood to control about 4 per cent of the British company, up from 3.1 per cent following a high volume of trades on Friday. The activist fund is calling on De La Rue's management to come up with a strategy that will prepare it for the future by focusing more on selling its technology. - The Daily Mail
Read moreLondon close: FTSE mixed as Unilever flies after rebuffed Kraft Heinz bid
17th Feb 2017 17:15
(ShareCast News) - London stocks closed mixed after a Friday session that saw blue-chip consumer goods giant Unilever fly higher after it slapped away a $143bn offer from Kraft Heinz, which has indicated it will return to the table. The rebuffed offer -- $50 a share in a mix of cash and shares -- wa
Read moreGSK upbeat on new HIV drug test results
14th Feb 2017 07:20
(ShareCast News) - GlaxoSmithKline announced on Tuesday that its majority-owned specialist HIV company ViiV Healthcare, which was established with Pfizer and Shionogi as shareholders, had released detailed study results from one of its phase III programme. The FTSE 100 drugmaker said the specific pr
Read more